Hence, the presence of intratumoral T lymphocytes is necessary but clearly not sufficient for a response to immune checkpoint inhibitors [52], which makes treatment responses in BRCA2-mutated prostate cancer difficult to predict. The gene discussed is BRCA2; the disease is prostate cancer.